Log in to search using one of your social media accounts:

 

Norvir Soft Gelatin Capsules (Ritonavir) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - July 14, 2017 Category: Drugs & Pharmacology Source Type: news

Payment delays by NACO causing HIV drugs scarcity
Cipla, the sole producer of lopinavir/ritonavir, a combination HIV drug prescribed for paediatric patients, has stopped manufacturing it over non-clearance of arrears by NACO. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - March 6, 2017 Category: Pharmaceuticals Source Type: news

AbbVie ’s VIEKIRAX + EXVIERA receives positive opinion for eight-week treatment of GT1b HCV
AbbVie has received a positive opinion for a shorter, eight-week treatment of VIEKIRAX (ombitasvir / paritaprevir / ritonavir tablets) + EXVIERA (dasabuvir tablets) as an option for previously untreated adult patients with genotype 1b (GT1b) chronic … (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - February 28, 2017 Category: Pharmaceuticals Source Type: news

Merck ’s Doravirine, an Investigational Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI) for the Treatment of HIV-1 Infection, Met Primary Efficacy Endpoint in Pivotal Phase 3 Trial
Dateline City: KENILWORTH, N.J. Data Presented at CROI Showed Doravirine Was Non-inferior to Ritonavir-boosted Darunavir in Treatment-na ïve Adults after 48 weeks of TreatmentKENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced results of a pivotal Phase 3 clinical trial evaluating the safety and efficacy of doravirine (MK-1439), an investigational non-nucleoside reverse transcriptase inhibitor (NNRTI).Language: EnglishContact: MerckMedia:Doris Li, 908-246-5701Carmen de Gourville, 267-664-0146orInvestors:Teri Loxam, 908-740-198...
Source: Merck.com - Research and Development News - February 14, 2017 Category: Pharmaceuticals Tags: Research and Development News Corporate News Latest News #Merck #MRK $MRK Doravirine HIV MSD NYSE:MRK Source Type: news

Efficacy of DRV/r Monotherapy vs DRV/r With Two NRTIs Efficacy of DRV/r Monotherapy vs DRV/r With Two NRTIs
How does darunavir/ritonavir monotherapy compare with DRV/r-based triple ART in terms of efficacy and safety?HIV Medicine (Source: Medscape Hiv-Aids Headlines)
Source: Medscape Hiv-Aids Headlines - January 11, 2017 Category: Infectious Diseases Tags: HIV/AIDS Journal Article Source Type: news

Kaletra Capsules (Lopinavir, Ritonavir Capsules) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - December 8, 2016 Category: Drugs & Pharmacology Source Type: news

Norvir (Ritonavir Capsules, Oral Solution) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - December 8, 2016 Category: Drugs & Pharmacology Source Type: news

Norvir Soft Gelatin Capsules (Ritonavir) - new on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - December 7, 2016 Category: Drugs & Pharmacology Source Type: news

Darunavir/Ritonavir in HIV-1-Infected Pregnant Women Darunavir/Ritonavir in HIV-1-Infected Pregnant Women
How does pregnancy affect the pharmacokinetics of this antiretroviral regimen?HIV Medicine (Source: Medscape Hiv-Aids Headlines)
Source: Medscape Hiv-Aids Headlines - November 9, 2016 Category: Infectious Diseases Tags: HIV/AIDS Journal Article Source Type: news

Ombitasvir/Paritaprevir/Ritonavir Regimen for Hepatitis C Ombitasvir/Paritaprevir/Ritonavir Regimen for Hepatitis C
This combination drug regimen proved highly effective for treatment of chronic HCV infection, even in difficult-to-treat populations and individuals with advanced disease.Alimentary Pharmacology & Therapeutics (Source: Medscape General Surgery Headlines)
Source: Medscape General Surgery Headlines - November 8, 2016 Category: Surgery Tags: Gastroenterology Journal Article Source Type: news

A Study of DRV/r for HIV Post-Exposure Prophylaxis A Study of DRV/r for HIV Post-Exposure Prophylaxis
Should ritonavir-boosted darunavir be considered as part of a HIV post-exposure prophylaxis regimen?HIV Medicine (Source: Medscape Hiv-Aids Headlines)
Source: Medscape Hiv-Aids Headlines - October 4, 2016 Category: Infectious Diseases Tags: HIV/AIDS Journal Article Source Type: news

AbbVie Presents Data on Eight-Week Treatment of VIEKIRAX(R) (ombitasvir/paritaprevir/ritonavir tablets) + EXVIERA(R) (dasabuvir tablets) in Patients with Genotype 1b Chronic Hepatitis C
NORTH CHICAGO, Ill., Sept. 23, 2016 -- (Healthcare Sales & Marketing Network) -- AbbVie (ABBV), a global biopharmaceutical company, today announced new data showing high response rates with just eight weeks of VIEKIRAX® (ombitasvir/paritaprevir/ritona... Biopharmaceuticals AbbVie, hepatitis C, VIEKIRAX, EXVIERA (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - September 23, 2016 Category: Pharmaceuticals Source Type: news

Improvement of Lipoatrophy by Switching From EFV to LPV/r Improvement of Lipoatrophy by Switching From EFV to LPV/r
Switching HIV patients with lipoatrophy from efavirenz to lopinavir/ritonavir may affect positive changes in limb fat.HIV Medicine (Source: Medscape Hiv-Aids Headlines)
Source: Medscape Hiv-Aids Headlines - September 20, 2016 Category: Infectious Diseases Tags: HIV/AIDS Journal Article Source Type: news

Interaction Between EE2/DSG and LPV/r in HIV+ Adolescents Interaction Between EE2/DSG and LPV/r in HIV+ Adolescents
Could oral contraceptives containing ethinyl estradiol/desogestrel compromise the effectiveness of lopinavir/ritonavir-based therapy?JAIDS: Journal of Acquired Immune Deficiency Syndromes (Source: Medscape Hiv-Aids Headlines)
Source: Medscape Hiv-Aids Headlines - August 24, 2016 Category: Infectious Diseases Tags: HIV/AIDS Journal Article Source Type: news

AbbVie Receives U.S. FDA Approval of Once-Daily VIEKIRA XR(TM) (dasabuvir, ombitasvir, paritaprevir and ritonavir) for the Treatment of Genotype 1 Chronic Hepatitis C
NORTH CHICAGO, Ill., July 25, 2016 -- (Healthcare Sales & Marketing Network) -- AbbVie (ABBV), a global biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has approved a New Drug Application (NDA) for VIEKIRA XR™ (... Biopharmaceuticals, FDAAbbVie, VIEKIRA XR, VIEKIRA PAK, hepatitis C (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - July 26, 2016 Category: Pharmaceuticals Source Type: news

AbbVie Receives U.S. FDA Approval of Once-Daily Viekira XR (dasabuvir, ombitasvir, paritaprevir and ritonavir) for the Treatment of Genotype 1 Chronic Hepatitis C
NORTH CHICAGO, Ill., July 25, 2016 /PRNewswire/ -- AbbVie (NYSE: ABBV), a global biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has approved a New Drug Application (NDA) for Viekira XR (dasabuvir,... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - July 25, 2016 Category: Drugs & Pharmacology Source Type: news

CHMP Grants Positive Opinion for Shorter Treatment Duration with AbbVie's VIEKIRAX(R) (ombitasvir/paritaprevir/ritonavir tablets) for Patients with Genotype 4 Chronic Hepatitis C with Compensated Cirrhosis (Child-Pugh A)
NORTH CHICAGO, Ill., July 25, 2016 -- (Healthcare Sales & Marketing Network) -- AbbVie (ABBV), a global biopharmaceutical company, announced today that the European Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has... Biopharmaceuticals, RegulatoryAbbVie, hepatitis C, VIEKIRAX (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - July 25, 2016 Category: Pharmaceuticals Source Type: news

FDA Clears Darunavir (Prezista) for Pregnant Women With HIV FDA Clears Darunavir (Prezista) for Pregnant Women With HIV
Data show darunavir, when taken with ritonavir, is safe, well tolerated, and effective during pregnancy and the postpartum period. FDA Approvals (Source: Medscape Pharmacist Headlines)
Source: Medscape Pharmacist Headlines - July 21, 2016 Category: Drugs & Pharmacology Tags: HIV/AIDS News Alert Source Type: news

FDA Clears Darunavir (Prezista) for Pregnant Women With HIVFDA Clears Darunavir (Prezista) for Pregnant Women With HIV
Data show darunavir, when taken with ritonavir, is safe, well tolerated, and effective during pregnancy and the postpartum period. FDA Approvals (Source: Medscape Pharmacist Headlines)
Source: Medscape Pharmacist Headlines - July 21, 2016 Category: Drugs & Pharmacology Tags: HIV/AIDS News Alert Source Type: news

ViiV reports ARIA Phase IIIb trial shows superior efficacy for Triumeq to treat HIV
ViiV Healthcare reported that phase IIIb of the ARIA study showed superior efficacy for Triumeq (dolutegravir / abacavir / lamivudine) compared with atazanavir boosted with ritonavir (ATV/r), along with tenofovir disoproxil fumarate / emtricitabine (… (Source: Drug Development Technology)
Source: Drug Development Technology - July 18, 2016 Category: Pharmaceuticals Source Type: news

Viekira Pak (Ombitasvir, Paritaprevir, and Ritonavir tablets; Dasabuvir Tablets) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - May 2, 2016 Category: Drugs & Pharmacology Source Type: news

Technivie (Ombitasvir, Paritaprevir and Ritonavir Tablets) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - May 2, 2016 Category: Drugs & Pharmacology Source Type: news

AbbVie Announces Real-World Data with VIEKIRAX(R) (ombitasvir/paritaprevir/ritonavir tablets) and EXVIERA(R) (dasabuvir tablets) from Large German Hepatitis C-Registry
VIEKIRAX and EXVIERA achieved 96 percent SVR12 in genotype 1 and 100 percent in genotype 4 chronic hepatitis C virus infected patients in a large ongoing real-world study(1) Data support findings from previous HCV Phase 3 clinical trials with VIEKIRAX a... BiopharmaceuticalsAbbVie, hepatitis C, VIEKIRAX, EXVIERA (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - April 15, 2016 Category: Pharmaceuticals Source Type: news

Comunicado de la FDA sobre la seguridad de los medicamentos: Importantes interacciones entre el medicamento Victrelis (boceprevir) y los medicamentos inhibidores de la proteasa del virus de inmunodeficiencia humana (VIH) reforzados con ritonavir
El 8 de febrero del 2012, la Administración de Alimentos y Medicamentos de Estados Unidos (FDA por sus siglas en inglés) notificó a los profesionales de la salud y a los pacientes que la interacción entre Victrelis (boceprevir), un medicamento inhibidor de la proteasa del virus de hepatitis C (VHC), y ciertos inhibidores de la proteasa del virus de inmunodeficiencia humana (VIH) reforzados con ritonavir (atazanavir, lopinavir, darunavir) tiene el potencial de reducir la eficacia de dichos medicamentos cuando se usan conjuntamente (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - March 4, 2016 Category: Drugs & Pharmacology Source Type: news

Efavirenz linked with higher bone mass in children with HIV
BOSTON – Switching HIV-infected South African children from ritonavir-boosted lopinavir (LPV/r) to efavirenz (EFV)-based antiretroviral therapy improved bone mineral content in the children, compared... (Source: Pediatric News)
Source: Pediatric News - February 25, 2016 Category: Journals (General) Source Type: news

Comunicado de la FDA sobre la seguridad de los medicamentos: Información actualizada sobre la interacción entre el medicamento Victrelis (boceprevir) y ciertos medicamentos reforzados inhibidores de la proteasa del VIH
El 26 de abril del 2012, la Administración de Alimentos y Medicamentos de Estados Unidos (FDA por sus siglas en inglés) informó al público que, en estos momentos, no se recomienda tomar conjuntamente Victrelis (boceprevir), un inhibidor de la proteasa del virus de la hepatitis C (VHC) junto con ciertos inhibidores de la proteasa del virus de la inmunodeficiencia humana VIH reforzados con ritonavir, por la posibilidad de reducir la eficacia de los medicamentos, lo que puede desencadenar el aumento del VHC o VIH en la sangre (carga viral). (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - January 19, 2016 Category: Drugs & Pharmacology Source Type: news

FDA Updates Saquinavir Labeling
“FDA approved changes to the Invirase (saquinavir mesylate) label to provide update[s] for drugs that are contraindicated or interact with Invirase/ritonavir." “Also a warning was added to state cobicistat is not recommended for concomitant use with Invirase.” The updated labeling will be available at the FDA website. More information is available: FDA: Press release AIDSinfo: Patient fact sheet on saquinavir (Source: AIDSinfo At-a-Glance: Offering Information on HIV/AIDS Treatment, Prevention, and Research, A Service of the U.S. Department of Health and Human Services (DHHS))
Source: AIDSinfo At-a-Glance: Offering Information on HIV/AIDS Treatment, Prevention, and Research, A Service of the U.S. Department of Health and Human Services (DHHS) - January 8, 2016 Category: Infectious Diseases Source Type: news

South Africa: Aids Day Highlights Need to Fix Patents Law
[News24Wire] The country's patent law is yet again under the microscope in light of World Aids Day and following the recent shortage of HIV medicine Lopinavir/Ritonavir (LPV/r), which is a life-line for nearly 10% of the country's approximately 3 million people on HIV treatment. (Source: AllAfrica News: Health and Medicine)
Source: AllAfrica News: Health and Medicine - December 1, 2015 Category: African Health Source Type: news

CHMP Backs Generic Lopinavir/Ritonavir Mylan for HIVCHMP Backs Generic Lopinavir/Ritonavir Mylan for HIV
Studies demonstrate the satisfactory quality of Lopinavir/Ritonavir Mylan and its bioequivalence to the reference product Kaletra, the committee said. International Approvals (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - November 20, 2015 Category: Consumer Health News Tags: HIV/AIDS News Alert Source Type: news

Viekira Pak Results Reassuring for Compensated CirrhosisViekira Pak Results Reassuring for Compensated Cirrhosis
For patients with genotype 1 hepatitis C infection and cirrhosis, the combination of ombitasvir, paritaprevir, and ritonavir plus dasabuvir, with or without ribavirin, is safe and effective. Medscape Medical News (Source: Medscape Gastroenterology Headlines)
Source: Medscape Gastroenterology Headlines - November 17, 2015 Category: Gastroenterology Tags: Gastroenterology News Source Type: news

Switch to Efavirenz-based ART Effective Option in KidsSwitch to Efavirenz-based ART Effective Option in Kids
A new study has found that switching to efavirenz-based ART vs continuing on ritonavir-boosted lopinavir-based ART was not tied to higher rates of viral rebound and failure in children. Medscape Medical News (Source: Medscape Infectious Diseases Headlines)
Source: Medscape Infectious Diseases Headlines - November 5, 2015 Category: Infectious Diseases Tags: HIV/AIDS News Source Type: news

South Africa Should Override Patent on Key HIV Medicine After Widespread Stock Out Problem
Press releaseSouth Africa Should Override Patent on Key HIV Medicine After Widespread Stock Out Problem October 28, 2015 JOHANNESBURG—After six months of persistent supply problems with the key HIV medicine lopinavir/ritonavir (LPV/r), the international medical humanitarian organization Doctors Without Borders/Médecins Sans Frontières (MSF) urged the South African government to put the public’s health first and override pharmaceutical company AbbVie’s patent with a "compulsory licence," in order to allow generic versions of LPV/r to be used in the country. (Source: MSF News)
Source: MSF News - October 28, 2015 Category: Global & Universal Authors: Elias Primoff Source Type: news

South Africa: Red Flag Over HIV Medicine Stock Out
[News24Wire] Doctors Without Borders wants the South African government to issue a landmark compulsory license to allow generic manufacturers to come to the aid of thousands of HIV patients in need of Lopinavir/Ritonavir (LPV/r). (Source: AllAfrica News: HIV-Aids and STDs)
Source: AllAfrica News: HIV-Aids and STDs - October 28, 2015 Category: Infectious Diseases Source Type: news

FDA Updates Atazanavir Oral Powder Label
"On September 24, 2015, FDA approved revisions to the Reyataz (atazanavir) oral powder label to include dosing recommendations for patients three months and older weighing at least 5 kg. This represents the addition of a new pediatric weight band. Previously the oral powder formulation was for patients three months and older weighing at least 10 kg.   "Reyataz oral powder must be taken with ritonavir and is not recommended for use in children who weigh less than 5 kg."   The updated labeling will be available at the FDA website.   More information is available: FDA: Press release AIDSinfo...
Source: AIDSinfo At-a-Glance: Offering Information on HIV/AIDS Treatment, Prevention, and Research, A Service of the U.S. Department of Health and Human Services (DHHS) - October 9, 2015 Category: Infectious Diseases Source Type: news

AbbVie's VIEKIRAX(R) (ombitasvir/paritaprevir/ritonavir tablets) Receives Approval in Japan for the Treatment of Genotype 1 Chronic Hepatitis C
New interferon and ribavirin-free treatment option for patients with most common type of hepatitis in Japan, genotype 1 chronic hepatitis C, including those with compensated cirrhosis[1] VIEKIRAX consists of a 12-week, two direct-acting antiviral, fixed... Biopharmaceuticals, RegulatoryAbbVie, VIEKIRAX, ombitasvir, paritaprevir, ritonavir (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - September 28, 2015 Category: Pharmaceuticals Source Type: news

Technivie (Ombitasvir, Paritaprevir and Ritonavir Tablets) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - September 21, 2015 Category: Drugs & Pharmacology Source Type: news

Viekira Pak (ombitasvir, paritaprevir, ritonavir, and dasabuvir)
Title: Viekira Pak (ombitasvir, paritaprevir, ritonavir, and dasabuvir)Category: MedicationsCreated: 8/14/2015 12:00:00 AMLast Editorial Review: 8/14/2015 12:00:00 AM (Source: MedicineNet Digestion General)
Source: MedicineNet Digestion General - August 14, 2015 Category: Nutrition Source Type: news

Technivie (ombitasvir, paritaprevir and ritonavir)
Title: Technivie (ombitasvir, paritaprevir and ritonavir)Category: MedicationsCreated: 8/14/2015 12:00:00 AMLast Editorial Review: 8/14/2015 12:00:00 AM (Source: MedicineNet Digestion General)
Source: MedicineNet Digestion General - August 14, 2015 Category: Nutrition Source Type: news

Technivie (ombitasvir, paritaprevir and ritonavir)
Title: Technivie (ombitasvir, paritaprevir and ritonavir)Category: MedicationsCreated: 8/14/2015 12:00:00 AMLast Editorial Review: 8/14/2015 12:00:00 AM (Source: MedicineNet Medications General)
Source: MedicineNet Medications General - August 14, 2015 Category: Drugs & Pharmacology Source Type: news

Technivie (Ombitasvir, Paritaprevir, Ritonavir) for the Treatment of Genotype 4 Chronic Hepatitis C
Technivie (ombitasvir, paritaprevir and ritonavir) is the first direct-acting antiviral drug approved for the treatment of genotype 4 (GT4) chronic hepatitis C virus (HCV) infection in the US. (Source: Drug Development Technology)
Source: Drug Development Technology - August 11, 2015 Category: Pharmaceuticals Source Type: news

There May Have Been a Major Breakthrough in MERS Treatment
Two existing and widely available drugs may prove to be effective treatments for Middle East Respiratory Syndrome (MERS), new research published by the University of Hong Kong suggests. According to the South China Morning Post, the medicines—lopinavir with ritonavir and a type of interferon—were tested on marmosets, small monkeys that a 2014 U.S. study concluded would be the best subject for MERS trials because of the way their reactions to the virus mimics human illness. The drugs, currently used to treat HIV and sclerosis, were found to be effective in curing MERS-infected marmosets. The research is the firs...
Source: TIME.com: Top Science and Health Stories - July 28, 2015 Category: Consumer Health News Authors: alissagreenberg Tags: Uncategorized Hong Kong medicine MERS monkeys Science South Korea Source Type: news

Interferon-Free Treatment for HCV Genotype 4 Approved (FREE)
By Kristin J. Kelley Edited by Susan Sadoughi, MD The FDA has approved a ombitasvir/paritaprevir/ritonavir tablet (marketed as Technivie) for treating hepatitis C virus genotype 4 in patients without cirrhosis or scarring. The … (Source: Physician's First Watch current issue)
Source: Physician's First Watch current issue - July 27, 2015 Category: Primary Care Source Type: news

FDA Clears Two New Oral Drugs for Hepatitis C FDA Clears Two New Oral Drugs for Hepatitis C
Technivie, for genotype 4 infection, combines ombitasvir, paritaprevir, and ritonavir and is for use with ribavirin. Daclatasvir, for use with sofosbuvir, is for genotype 3 infection. FDA Approvals (Source: Medscape Gastroenterology Headlines)
Source: Medscape Gastroenterology Headlines - July 25, 2015 Category: Gastroenterology Tags: Infectious Diseases News Alert Source Type: news

FDA approves Technivie for treatment of chronic hepatitis C genotype 4
The U.S. Food and Drug Administration today approved Technivie (ombitasvir, paritaprevir and ritonavir) for use in combination with ribavirin for the treatment of hepatitis C virus (HCV) genotype 4 infections in patients without scarring and poor liver function (cirrhosis). (Source: Food and Drug Administration)
Source: Food and Drug Administration - July 24, 2015 Category: American Health Source Type: news

lopinavir and ritonavir, Kaletra
Title: lopinavir and ritonavir, KaletraCategory: MedicationsCreated: 3/12/2001 12:00:00 AMLast Editorial Review: 7/9/2015 12:00:00 AM (Source: MedicineNet HIV General)
Source: MedicineNet HIV General - July 9, 2015 Category: Infectious Diseases Source Type: news

FDA Updates Kaletra Labeling
"The Kaletra (lopinavir/ritonavir) product labeling was updated to include drug-drug interaction information with etravirine, rilpivirine and simeprevir and to update the Use in Specific Populations, Pediatric Use subsection with information from a clinical trial that investigated the use of a once daily dosing regimen."   The updated labeling will be available soon at the FDA website.   More information is available: FDA: Press release AIDSinfo: Patient fact sheet on Kaletra (Source: AIDSinfo At-a-Glance: Offering Information on HIV/AIDS Treatment, Prevention, and Research, A Service of the U.S. D...
Source: AIDSinfo At-a-Glance: Offering Information on HIV/AIDS Treatment, Prevention, and Research, A Service of the U.S. Department of Health and Human Services (DHHS) - July 2, 2015 Category: Infectious Diseases Source Type: news

FDA Approves First Pediatric Lopinavir/Ritonavir Oral Pellets for the Treatment of AIDS in Infants and Young Children
Mumbai, India - June 3, 2015 --Cipla Limited, a global pharmaceutical company which uses cutting edge technology and innovation to meet the everyday needs of all patients, today announced that it has received US FDA approval for an innovative... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - June 3, 2015 Category: Pharmaceuticals Source Type: news

Cipla gets USFDA nod for Lopinavir, Ritonavir oral pellets
Cipla has received approval from US health regulator USFDA for Lopinavir and Ritonavir oral pellets used for treating AIDS in infants and young children. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - June 3, 2015 Category: Pharmaceuticals Source Type: news

Interferon-free Regimen for Genotype-4 Chronic Hepatitis CInterferon-free Regimen for Genotype-4 Chronic Hepatitis C
An all-oral, interferon-free regimen consisting of ombitasvir, paritaprevir and ritonavir is effective at treating patients with genotype-4 chronic hepatitis C virus (HCV), according to a new report from AbbVie. Reuters Health Information (Source: Medscape Gastroenterology Headlines)
Source: Medscape Gastroenterology Headlines - April 13, 2015 Category: Gastroenterology Tags: Infectious Diseases News Source Type: news

Updated HHS Adult and Adolescent Antiretroviral Treatment Guidelines Released
The HHS Panel on Antiretroviral Guidelines for Adults and Adolescents announces the release of the updated Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents. Key updates to the guidelines include additions and changes to the following guideline sections: What to Start: Significant changes to the list of Recommended, Alternative, and Other regimens for treatment-naive patients prompted by recent findings from clinical trials and cohort studies, as well as experience in clinical practice. Addition of a new table to assist clinicians in selecting an initial ARV regimen based on...
Source: AIDSinfo At-a-Glance: Offering Information on HIV/AIDS Treatment, Prevention, and Research, A Service of the U.S. Department of Health and Human Services (DHHS) - April 8, 2015 Category: Infectious Diseases Source Type: news